Q’Apel Medical Announces CE Mark Approval for Armadillo SelectFlex™ Neurovascular Access System

• Patented SelectFlex™ Technology allows operators to achieve the ideal balance of trackability and support on demand to navigate complex neurovasculature
• System enables biaxial approach, regardless of access site, to eliminate complexity and cost of conventional configurations

Fremont, CA – January 13, 2025 – Q’Apel Medical (Q’Apel), a privately held medical device company
focused on revolutionizing neurovascular interventions, today announced it has received CE mark
certification for its Armadillo SelectFlex™ Neurovascular Access System. The first-of-its-kind 7F
system features the patented SelectFlex™ Technology and is indicated for the introduction of
interventional devices into the neurovasculature.

“Neurovascular access can be extremely challenging. The tortuous anatomy requires flexibility to
navigate the tight twists and turns, however, flexible access catheters tend to lack the support and
stability required for device delivery once positioned,” commented Pascal Jabbour, MD, FAANS,
FACS, FAHA, The Angela and Richard T. Clark Distinguished Professor of Neurological Surgery and
Radiology, Division Chief of Neurovascular Surgery & Endovascular Neurosurgery at Thomas
JeWerson University Hospital in Philadelphia, PA. “Armadillo provides a one-and-done solution that
simplifies access procedures. It is designed to place full control in the hands of the operator as it
allows users to transform the catheter from highly trackable to highly supportive as needed
throughout the procedure with the simple injection or withdrawal of just 0.2cc of saline.”

The Armadillo Neurovascular Access System with SelectFlex™ Technology delivers the versatility
required for physicians to confidently tackle a wide range of neurovascular interventions. Regardless
of access site, the low-profile 7F catheter enables a biaxial approach to accelerate delicate
interventions and eliminate the complexity and cost of conventional tri-axial configurations.

“The Armadillo Neurovascular Access System with SelectFlex™ Technology addresses the
shortcomings of currently available neurovascular access catheters. We believe it provides a novel
option that allows hospitals to standardize device usage, decrease inventory constraints and reduce
cost per procedure,” stated Jodie Fam, CEO of Q’Apel Medical. “I thank our incredible team for their
eWorts to achieve this critical milestone. We look forward to building upon Armadillo’s U.S.
commercial success as we prepare to expand our international portfolio and deliver this meaningful
solution to the European market, and others, in the coming months.”